Seventh Annual Anniversary Issue - 197 pages !
Introduction - pgs. 1-9
Company Updates & Rankings - pgs. 10-190
Macro Market Commentary "Irony and a Bear Suit " - pgs. 191-195
BSR Model Portfolio Update - pgs. 196-197

It's the big issue!

Welcome to our once-yearly effort to review all the companies in Biotech Stock Research's coverage universe. Our company turned nine this past May, but this is the seventh anniversary of the creation of the Biotech Stock Research Model Portfolio. Its creation was the dawn of our biotech-centric coverage, making this our Seventh Annual Anniversary Issue.

The companies appear in a specific order. Our research is predicated on the idea the only smart investment in development-stage biotechnology companies is a well-diversified one. The BSR Model Portfolio is the most visible manifestation of this important concept. Without limiting the importance of that point, we also realize most of our Subscribers will need to pick and choose among companies in order to begin the diversification process. We've organized the issue with the diversification process in mind. We've placed the companies in order beginning with those most deserving of being a member of a diversified portfolio.

In this issue of Biotech Monthly, we update our coverage on (in alphabetical order):

Adolor (ADLR)
Altus Pharma (ALTU)
Amicus Therapeutics (FOLD)
BioMarin (BMRN)
CombinatoRx (CRXX)
Corcept Therapeutics (CORT)
Dendreon (DNDN)
Discovery Labs (DSCO)
Dynavax Technologies (DVAX)
Hana Biosciences (HNAB)
Indevus (IDEV)
Medarex (MEDX)
Oncolytics Biotech (ONCY)
Osmetech (London:OMH)
OXiGENE (OXGN)
Raptor Pharmaceuticals (RPTP)
Repros Therapeutics (RPRX)
Resverlogix (Toronto:RVX)
SciClone (SCLN)
Seattle Genetics (SGEN)
Targeted Genetics (TGEN)
ViRexx (REX)
YM Biosciences (YMI)
ZymoGenetics (ZGEN)